Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 2/20 | 0.71 |
| ▸ | CRBN | Q96SW2 | 8/20 | 0.69 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.68 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.68 |
| ▸ | GSK3B | P49841 | 3/20 | 0.58 |
| ▸ | BRD4 | O60885 | 3/20 | 0.57 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.56 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17859033 | 1.00 | STAT3 (0.71) | STAT3CRBNDDB1HDAC1HDAC6 | |
| SCHEMBL29622211 | 0.99 | STAT3 (0.70) | STAT3CRBNDDB1HDAC1HDAC6 | |
| SCHEMBL29622326 | 0.99 | STAT3 (0.70) | STAT3CRBNDDB1HDAC1HDAC6 | |
| Ammonia Solution, Strong SCHEMBL27196529 | 0.99 | STAT3 (0.70) | STAT3CRBNDDB1HDAC1HDAC6 | |
| Hydrochloric Acid SCHEMBL30893263 | 0.99 | STAT3 (0.70) | STAT3CRBNDDB1HDAC1HDAC6 | |
| SCHEMBL24142023 | 0.99 | STAT3 (0.70) | STAT3CRBNDDB1HDAC1HDAC6 | |
| SCHEMBL17859010 | 0.99 | STAT3 (0.70) | STAT3CRBNDDB1HDAC1HDAC6 | |
| SCHEMBL17859058 | 0.99 | STAT3 (0.70) | STAT3CRBNDDB1HDAC1HDAC6 | |
| SCHEMBL21070244 | 0.99 | STAT3 (0.70) | STAT3CRBNDDB1HDAC1HDAC6 | |
| SCHEMBL29622083 | 0.99 | STAT3 (0.70) | STAT3CRBNDDB1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4034132-B1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | DANA FARBER CANCER INST INC (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12551563-B2 | ERK5 degraders as therapeutics in cancer and inflammatory diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| WO-2024027792-A1 | PROTEIN KINASE DEGRADING AGENT, MEDICAMENT AND USE | SHENZHEN NEWDEL BIOTECH CO., LTD. (CN) | 2024-02-08 | — | — | WO | disclosed |
| CN-117510504-A | Protein kinase degradation agent, medicine and application | 深圳市新樾生物科技有限公司 | 2024-02-06 | — | — | CN | disclosed |
| WO-2022086937-A9 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20220378919-A1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-01 | — | — | US | disclosed |
| WO-2022086937-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF ENL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551563-B2 | ERK5 degraders as therapeutics in cancer and inflammatory diseases | OXSR1, MAPK1, NGFR | STAT3 115/4885CRBN 139/4885DDB1 2103/4885 |
| US-20220378919-A1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | MAPKAPK5, DUSP5, MAP3K5 | STAT3 325/4885CRBN 813/4885DDB1 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.